Diltiazem and Esmolol interaction
Diltiazem and Esmolol: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Diltiazem (DILTIAZEM HYDROCHLORIDE in SODIUM CHLORIDE) label · effective 2025-04-15
• Concomitant administration with IV beta-blockers.
Beta-blockers Increased risk of bradycardia, AV block, and depression of contractility.
Beta-blocker may need to be decreased [see Warnings and Precautions (5.1, 5.2)].
• Beta-Blockers: Monitor for bradycardia, AV block, and depression of contractility.
From the Esmolol (BREVIBLOC) label · effective 2025-03-14
• IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC injection in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC injection and intravenous verapamil.
• Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to BREVIBLOC injection ( 4 , 7 )
• Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension.
• Antihypertensive agents: Risk of rebound hypertension ( 7 )
If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.